Precision Oncology Comes of Age: Tumor-Agnostic Approaches
Presented by Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
From Winship Cancer Institute of Emory University, Atlanta, Georgia
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):221–225 |
© 2020 Harborside™
Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support precision medicine advances.
For access to the full length article, please sign in